Fasting Mimicking Diet With Chemotherapy in Patients With Leukemia
The Effect of Fasting Mimicking Diet With Chemotherapy on the Number of Blasts and Platelets and Quality of Life in Patients With Acute Lymphoid Leukemia and Acute Myeloid Leukemia
1 other identifier
interventional
40
1 country
2
Brief Summary
The goal of this clinical trial is to investigate The effect of fasting mimicking diet with chemotherapy on the number of blasts and platelets and quality of life in patients with acute lymphoid leukemia and acute myeloid leukemia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2023
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 2, 2023
CompletedFirst Submitted
Initial submission to the registry
February 26, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2024
CompletedFirst Posted
Study publicly available on registry
April 9, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2024
CompletedApril 9, 2024
April 1, 2024
9 months
February 26, 2024
April 7, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Blast cell count
the number of blast cell in perpheral blood
at 4th week
Quality of life
Measuring the quality of life using EORTC QLQ questionnaire
at the beginning and 4th week
Study Arms (2)
fasting mimicking diet
EXPERIMENTALthe intervention group that receive fasting mimicking diet with chemotherapy
control
NO INTERVENTIONthe control group that receive chemotherapy without any intervention
Interventions
Fasting mimicking diet is limited calorie diet to enhance the effectiveness of chemotherapy
Eligibility Criteria
You may qualify if:
- People who have recently been diagnosed with acute leukemia pathology and have been prescribed chemotherapy
- Willingness to cooperate
- BMI \>18.5
You may not qualify if:
- diabetes
- metastases to other organ
- Unwillingness to continue the study by patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Azita Hekmatdoost
Tehran, Middle East, 19835, Iran
Ehsan Hejazi
Tehran, 19839-63113, Iran
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ehsan Hejazi, PhD
Beheshti University of Medical Sciences
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principle Investigator
Study Record Dates
First Submitted
February 26, 2024
First Posted
April 9, 2024
Study Start
July 2, 2023
Primary Completion
April 1, 2024
Study Completion
May 1, 2024
Last Updated
April 9, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share